ICON Public (NASDAQ:ICLR) Price Target Lowered to $215.00 at Citigroup

ICON Public (NASDAQ:ICLR) had its target price dropped by Citigroup from $290.00 to $215.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Citigroup’s price objective indicates a potential upside of 42.32% from the stock’s current price.

ICLR has been the topic of a number of other reports. Barclays reduced their target price on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research note on Friday, February 21st. Robert W. Baird decreased their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group cut ICON Public from a “buy” rating to a “neutral” rating and cut their target price for the stock from $250.00 to $200.00 in a research note on Friday, March 21st. JPMorgan Chase & Co. decreased their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $259.00.

ICON Public Price Performance

Shares of NASDAQ:ICLR traded down $2.65 during midday trading on Monday, hitting $151.07. The company had a trading volume of 348,952 shares, compared to its average volume of 864,882. ICON Public has a twelve month low of $149.23 and a twelve month high of $347.72. The stock has a market cap of $12.20 billion, a price-to-earnings ratio of 15.83, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The business’s 50-day simple moving average is $186.79 and its 200-day simple moving average is $216.96.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, research analysts predict that ICON Public will post 13.38 earnings per share for the current year.

Institutional Trading of ICON Public

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sierra Ocean LLC acquired a new position in shares of ICON Public in the fourth quarter valued at approximately $29,000. Park Place Capital Corp boosted its position in ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares during the period. Private Trust Co. NA grew its stake in shares of ICON Public by 48.8% in the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares in the last quarter. GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the period. Finally, Horizon Investments LLC raised its stake in shares of ICON Public by 534.0% in the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 550 shares in the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.